Dear Colleagues! This is Asrar Qureshi’s Blog Post #1319 for Pharma Veterans. Pharma Veterans Blogs are published by Asrar Qureshi on its dedicated site https://pharmaveterans.com. Please email to pharmaveterans2017@gmail.com for publishing your contributions here.
Preamble
This post is based on a World Health Organization Report.. Link at the end.
WHO’s 2026 report, Measuring survival, driving change: advancing equity through the WHO Global Initiative for Childhood Cancer, examines one of the most striking inequalities in global health: children with cancer can face dramatically different chances of survival depending on where they live. The report introduces comparable five-year survival estimates for lymphoid leukaemia across 194 Member States and links better data to stronger policy and health-system action. WHO’s global target is at least 60% childhood-cancer survival by 2030.
Childhood Cancer: Why Where a Child Lives Should Not Determine Whether They Survive
Cancer is often associated with older age. But cancer also affects children, and when it does, the consequences are devastating not only for the child but for parents, siblings and entire communities. What makes childhood cancer particularly troubling is that survival is no longer simply a question of whether effective treatments exist. In many parts of the world, children with cancer can survive if they are diagnosed early, receive appropriate treatment and have access to quality supportive care. The problem is that these conditions are not equally available everywhere.
A Child’s Chances Should Not Depend on Geography
Perhaps the most disturbing feature of childhood cancer is the enormous difference in survival between countries. WHO reports that survival exceeds 80% in many high-income settings, while it remains below 30% in some low-resource countries.
Think about what this means. The disease is not necessarily fundamentally different because a child was born in one country rather than another. A child’s chances of surviving cancer can be heavily influenced by the health system into which that child happens to be born. That is not simply a medical problem. It is a systems problem.
Childhood Cancer Is Different
Children are not simply small adults. Childhood cancers have distinctive biological and clinical characteristics, and their diagnosis and treatment require specialized approaches. The WHO report emphasizes the unique characteristics and epidemiology of childhood cancers as part of understanding the global survival gap. This matters because treatment requires more than making medicines available.
A medicine sitting on a shelf does not save a child. A functioning healthcare system does.
The First Challenge: Diagnosing the Disease
One of the major barriers identified by WHO is timely diagnosis. Cancer can be difficult to recognize, particularly in primary-care settings where healthcare workers may encounter relatively few childhood cancer cases. Symptoms may resemble more common childhood illnesses.
If cancer is not recognized promptly, the child may move through several healthcare providers before reaching a specialist. Every delay matters.
The Second Challenge: Access to Treatment
Diagnosis alone is not enough. Once cancer is identified, the child needs appropriate treatment. This is where differences between health systems become even more consequential.
Specialized oncology services may be concentrated in major cities. Families living in rural or remote areas may have to travel long distances. Treatment may extend over months. Parents may have to stop working. Transport and accommodation may become unaffordable. Medicines may not always be consistently available. This is why WHO’s approach is broader than simply increasing the supply of cancer medicines. The objective is to strengthen the entire system that enables a child to receive appropriate care.
The Hidden Problem: Continuity of Care
Cancer treatment is rarely a single event. It is a journey.
Diagnosis is followed by treatment. Treatment requires monitoring. Complications may require urgent intervention. Patients need follow-up. And families need support throughout the process. A child who begins treatment but cannot complete it does not receive the full benefit of modern cancer care. WHO identifies barriers affecting timely diagnosis, access to treatment and continuity of care as persistent challenges.
This is a critical insight for health policymakers.
Data Can Change the Conversation
One of the most important contributions of the WHO report is its emphasis on data.
For many health problems, policymakers cannot manage what they cannot measure. Historically, reliable, comparable information about childhood-cancer outcomes has been limited in many countries.
WHO’s new country-comparable five-year survival estimates for lymphoid leukaemia across 194 Member States represent an important step toward filling this gap.
Data transforms a general concern into a management problem. That is why cancer registries and surveillance systems are not administrative luxuries. They are instruments of health policy.
The Importance of Population-Based Cancer Registries
WHO highlights the critical role of high-quality population-based cancer registries in generating the data needed for evidence-informed policymaking and monitoring progress. A strong registry can help governments understand the real burden of disease. Without reliable registration, countries may underestimate the number of children affected.
Data infrastructure should be viewed as part of healthcare infrastructure. A cancer registry may not look as visible as a new hospital. But over time, it can help determine where hospitals, specialists, medicines and other resources are most urgently required.
The CureAll Framework
WHO’s Global Initiative for Childhood Cancer uses the CureAll framework as a structured approach for strengthening childhood-cancer programmes. The framework is designed to support national planning, implementation, monitoring and evaluation and to help countries move toward better survival and reduced suffering.
Its significance lies in recognizing that no single intervention will close the survival gap. A country needs coordinated action. It needs political commitment. It needs appropriate treatment capacity. It needs systems for measuring progress. It needs partnerships. And it needs sustained investment. This is an important lesson for health-sector leaders.
The Pharmaceutical Industry Has a Role
The WHO report also has implications for the pharmaceutical industry. Pharmaceutical companies are important stakeholders in the childhood-cancer ecosystem, particularly in developing and supplying medicines, supporting research and contributing to healthcare capacity.
But the industry’s contribution should not be viewed solely through the traditional lens of product supply. The larger challenge is ensuring that effective therapies can actually reach children who need them.
There is also an opportunity for greater collaboration in research. Clinical research in childhood cancer faces particular challenges because patient populations are relatively small and specialized expertise is required.
The 60% Target Is More Than a Number
WHO’s Global Initiative for Childhood Cancer has established a global target of achieving at least 60% survival among children with cancer by 2030, while reducing inequities in outcomes.
Targets matter because they create accountability. But the real importance of the 60% target is not the number itself. It represents a commitment to narrowing the enormous gap between children who currently have very different chances of survival.
For countries with low survival rates, reaching the target will require more than incremental improvements. It will require coordinated transformation.
From Measuring Survival to Saving Lives
The title of the WHO report contains two powerful ideas: Measuring survival and driving change. The sequence matters.
First, measure, then understand the gaps, then identify the causes, then intervene, then measure again. This is the essence of evidence-based management. The lesson extends beyond childhood cancer.
The Real Measure of a Health System
A healthcare system should ultimately be judged not only by the sophistication of its hospitals or the availability of its technology. It should also be judged by whether a child in a disadvantaged community has a meaningful opportunity to receive timely, quality care.
That is the heart of the WHO report. Childhood cancer exposes an uncomfortable reality: Medical progress alone does not guarantee health progress.
A system in which data informs policy, primary care recognizes warning signs, referral pathways function, treatment is available and continuous, families are supported, and progress is measured transparently. Every child with cancer deserves that system.
Concluded.
Disclaimers: Pictures in these blogs are taken from free resources at Pexels, Pixabay, Unsplash, and Google. Credit is given where available. If a copyright claim is lodged, we shall remove the picture with appropriate regrets.
For most blogs, I research from several sources which are open to public. Their links are mentioned under references. There is no intent to infringe upon anyone’s copyrights. If, any claim is lodged, it will be acknowledged and duly recognized immediately.
Reference:
